To maintain the long view on protecting the pharma supply chain as we look to the next phase of the pandemic, we must take stock of what has evolved and how distributors can continue to provide stability, writes Heather Zenk. Every day, pharmaceutical distributors ensure the safe, efficient, and reliable delivery of 92 percent of the medicines purchased in the US, connecting 180,000 providers and pharmacies with 1,300 drug manufacturers nationwide.1 Now, amid COVID-19 – a global pandemic for which the world was not ready – it is both humbling and an honor to continue this work, despite many challenges. The US healthcare system, from pharma manufacturers and distributors to providers and pharmacists, has come together to make sure as many critical medications as possible reach the patients who need them most. As we look to the next phase of the pandemic response and maintain our long view on protecting the supply chain, it’s critical we take stock of what has already evolved and how distributors can continue to provide stability. That work includes protecting in-demand medicines, ensuring safe product handling, and supporting clinical trials. It also means partnering across the supply chain to anticipate the next set of provider and patient needs and planning for them now.

Click Here For Complete Article Text

• Cooperation

• Planning

• Process Management

• Distribution

• Health and Safety

• Partnership

• Pharmaceutical Executive

• 7/1/2020

• Article